دورية أكاديمية
P592 Effectiveness and safety of thioguanine in thiopurine-naïve Inflammatory Bowel Disease patients
| العنوان: | P592 Effectiveness and safety of thioguanine in thiopurine-naïve Inflammatory Bowel Disease patients |
|---|---|
| المؤلفون: | Crouwel, F, Bayoumy, A B, Mulder, C J J, Peters, J H C, Boekema, P J, Derijks, L J J, De Boer, S Y, van de Meeberg, P C, Ahmad, I, Buiter, H J C, de Boer, N K |
| المصدر: | Journal of Crohn's and Colitis ; volume 16, issue Supplement_1, page i529-i529 ; ISSN 1873-9946 1876-4479 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Gastroenterology, General Medicine |
| الوصف: | Background Currently thioguanine is considered as off-label rescue therapy for Inflammatory Bowel Disease (IBD) after conventional thiopurine failure. This study aimed to determine the safety, effectiveness and 12-month drug tolerability of thioguanine in thiopurine-naïve IBD patients. Methods We performed an analysis of our multicenter, retrospective cohort study including thiopurine-naïve IBD patients treated with thioguanine as first-line maintenance therapy without concomitant biological therapy. Clinical effectiveness was defined as a sustained clinical response (based on physician’s global assessment) without the (re-)initiation of concurrent biological therapy, corticosteroids or a IBD-related surgical intervention. All adverse events that occurred during follow-up were categorized by the Common Terminology Criteria for Adverse Events. Elevation of two concurrent liver tests were categorized as drug-induced liver injury. Results A total of 103 IBD patients (female 61%, Crohn’s disease 52%) were included with a median daily thioguanine dose of 20mg and median 6-thioguanine nucleotide (6-TGN) levels of 635 pmol/8x108 RBC (IQR 425–1100). Clinical effectiveness at 12 months was observed in 60 out of 99 patients (61%) and 80% of patients were still using thioguanine 12 months after initiation. Four patients did not reach the 12-month follow-up period but were in remission at time of data collection. Of the responding patients at 12 months 88% (N=53) remained responsive until the end of follow-up (median follow-up period 28 months, IQR 17–40 months). Forty-nine patients (48%) developed adverse events (grade 1 or 2), of which 24% graded as moderate (grade 2) and none as severe. Seven patients ceased therapy due to the occurrence of adverse events. Adverse events consisted mainly of elevated liver tests (26%) and gastrointestinal complaints (17%). An infection was documented in three patients, none of them requiring hospitalization. Pancytopenia occurred in two other patients with 6-TGN levels of ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/ecco-jcc/jjab232.718 |
| الإتاحة: | https://doi.org/10.1093/ecco-jcc/jjab232.718Test https://academic.oup.com/ecco-jcc/article-pdf/16/Supplement_1/i529/42253114/jjab232.718.pdfTest |
| حقوق: | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelTest |
| رقم الانضمام: | edsbas.1E627813 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/ecco-jcc/jjab232.718 |
|---|